SUSAN ROETHKE: Open Payments
NPI 1144401852 · PHILA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 20 payments from 12 companies in 2025. Trend: 2023 $462 · 2024 $267 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Novartis Pharmaceuticals Corporation | 4 | $74 |
| PFIZER INC. | 2 | $50 |
| Merck Sharp & Dohme LLC | 2 | $47 |
| Celgene Corporation | 2 | $46 |
| Eisai Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Astellas Pharma US Inc | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
Products named: OPDIVO, Xtandi, KEYTRUDA, PLUVICTO, Lenvima, SCEMBLIX, REBLOZYL, Vanflyta.
Industry payments across PA — which companies pay providers there.
